Annals of Surgical Oncology

, Volume 21, Issue 3, pp 843–849 | Cite as

Risk of Thyroid Cancer in Patients with Thyroiditis: A Population-Based Cohort Study

  • Chien-Liang Liu
  • Shih-Ping Cheng
  • Hui-Wen Lin
  • Yuen-Liang Lai
Endocrine Tumors

Abstract

Background

The causative relationship between autoimmune thyroiditis and thyroid cancer remains a controversial issue. The aim of this population-based study was to investigate the risk of thyroid cancer in patients with thyroiditis.

Methods

From the Longitudinal Health Insurance Database 2005 (LHID2005) of Taiwan, we identified adult patients newly diagnosed with thyroiditis between 2004 and 2009 (n = 1,654). The comparison cohort (n = 8,270) included five randomly selected age- and sex-matched controls for each patient in the study cohort. All patients were followed up from the date of cohort entry until they developed thyroid cancer or to the end of 2010. Multivariate Cox regression was used to assess the risk of developing thyroid cancer. A total of 1,000 bootstrap replicates were created for internal validation.

Results

A total of 35 patients developed thyroid cancer during the study period, of whom 24 were from the thyroiditis cohort and 11 were from the comparison cohort (incidence 353 and 22 per 100,000 person-years, respectively). After adjusting for potential confounding factors, the hazard ratio (HR) for thyroid cancer in patients with thyroiditis was 13.24 (95 % CI 6.40–27.39). Excluding cancers occurring within 1 year of follow-up, the HR remained significantly increased (6.64; 95 % CI 2.35–18.75). Hypothyroidism was not an independent factor associated with the occurrence of thyroid cancer.

Conclusions

We found an increased risk for the development of thyroid cancer after a diagnosis of thyroiditis, independent of comorbidities.

Keywords

Thyroid Cancer Thyroiditis Papillary Thyroid Cancer Autoimmune Thyroiditis Comparison Cohort 

Notes

Disclosures

The authors have no conflicts of interest to disclose.

References

  1. 1.
    Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Guarino V, Castellone MD, Avilla E, Melillo RM. Thyroid cancer and inflammation. Mol Cell Endocrinol. 2010;321:94–102.PubMedCrossRefGoogle Scholar
  3. 3.
    Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol. 2013;107:493–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg. 2013;205:691–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348:2646–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Ott J, Meusel M, Schultheis A, Promberger R, Pallikunnel SJ, Neuhold N, Hermann M. The incidence of lymphocytic thyroid infiltration and Hashimoto’s thyroiditis increased in patients operated for benign goiter over a 31-year period. Virchows Arch. 2011;459:277–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results National Cancer Data Registry. Surgery. 2010;148:1147-52.PubMedCrossRefGoogle Scholar
  8. 8.
    Konturek A, Barczynski M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg. 2013;398:389–94.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab. 2013;98:474–82.PubMedCrossRefGoogle Scholar
  10. 10.
    Lin HW, Tu YY, Lin SY, et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol. 2011;12:900–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med. 2008;148:258–67.PubMedCrossRefGoogle Scholar
  13. 13.
    National Health Research Institutes. National Health Insurance Research database, Taiwan. http://www.nhri.org.tw/nhird/en/index.htm. Accessed 1 May 2013.
  14. 14.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.PubMedCrossRefGoogle Scholar
  15. 15.
    Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg. 2001;25:632–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Gupta S, Patel A, Folstad A, et al. Infiltration of differentiated thyroid carcinoma by proliferating lymphocytes is associated with improved disease-free survival for children and young adults. J Clin Endocrinol Metab. 2001;86:1346–54.PubMedGoogle Scholar
  17. 17.
    Dvorkin S, Robenshtok E, Hirsch D, Strenov Y, Shimon I, Benbassat CA. Differentiated thyroid cancer is associated with less aggressive disease and better outcome in patients with coexisting Hashimotos thyroiditis. J Clin Endocrinol Metab. 2013;98:2409–14.PubMedCrossRefGoogle Scholar
  18. 18.
    Lee JH, Kim Y, Choi JW, Kim YS. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol. 2013;168:343–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Shattuck TM, Westra WH, Ladenson PW, Arnold A. Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma. N Engl J Med. 2005;352:2406–12.PubMedCrossRefGoogle Scholar
  20. 20.
    Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Fiore E, Rago T, Latrofa F, et al. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with l-thyroxine. Endocr Relat Cancer. 2011;18:429–37.PubMedCrossRefGoogle Scholar
  22. 22.
    Morris LG, Sikora AG, Tosteson TD, Davies L. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid. 2013;23:885-91.PubMedCrossRefGoogle Scholar
  23. 23.
    Udelsman R, Zhang Y. The epidemic of thyroid cancer in the United States: the role of endocrinologists and ultrasounds. Thyroid. 2013. doi: 10.1089/thy.2013.0257.Google Scholar
  24. 24.
    Zhu C, Zheng T, Kilfoy BA, et al. A birth cohort analysis of the incidence of papillary thyroid cancer in the United States, 1973–2004. Thyroid. 2009;19:1061–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Enewold LR, Zhou J, Devesa SS, et al. Thyroid cancer incidence among active duty U.S. military personnel, 1990–2004. Cancer Epidemiol Biomarkers Prev. 2011;20:2369–76.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980–2008. Thyroid. 2013;23:103–10.PubMedCrossRefGoogle Scholar
  27. 27.
    Carpi A, Rossi G, Romani R, et al. Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study. PLoS One. 2012;7:e47758.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Rizzo M, Sindoni A, Talamo Rossi R, et al. Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. Hormones (Athens). 2013;12:46–57.PubMedGoogle Scholar
  29. 29.
    Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem. 2010;17:3449–61.PubMedCrossRefGoogle Scholar
  30. 30.
    Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg. 2007;204:764–73, discussion 773–5.Google Scholar
  31. 31.
    Unger P, Ewart M, Wang BY, Gan L, Kohtz DS, Burstein DE. Expression of p63 in papillary thyroid carcinoma and in Hashimoto’s thyroiditis: a pathobiologic link? Hum Pathol. 2003;34:764–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto’s thyroiditis: a stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol. 2004;35:465–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Muzza M, Degl’Innocenti D, Colombo C, et al. The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol. 2010;72:702–8.CrossRefGoogle Scholar
  34. 34.
    Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology prize lecture. Eur J Endocrinol. 2006;155:645–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323–37.PubMedCrossRefGoogle Scholar
  36. 36.
    Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, Vitti P; AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010;16 Suppl 1:1–43.PubMedCrossRefGoogle Scholar
  37. 37.
    Sadowski SM, He M, Gesuwan K, et al. Prospective screening in familial nonmedullary thyroid cancer. Surgery. 2013. doi: 10.1016/j.surg.2013.06.019.PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Chien-Liang Liu
    • 1
    • 2
    • 3
  • Shih-Ping Cheng
    • 2
    • 3
    • 6
  • Hui-Wen Lin
    • 4
  • Yuen-Liang Lai
    • 3
    • 5
    • 7
    • 8
  1. 1.Mackay Junior College of Medicine, Nursing, and ManagementTaipeiTaiwan
  2. 2.Department of SurgeryMackay Memorial HospitalTaipeiTaiwan
  3. 3.School of MedicineMackay Medical CollegeTaipeiTaiwan
  4. 4.Department of MathematicsSoochow UniversityTaipeiTaiwan
  5. 5.Department of Radiation OncologyMackay Memorial HospitalTaipeiTaiwan
  6. 6.Graduate Institute of Medical Sciences and Department of PharmacologyTaipei Medical UniversityTaipeiTaiwan
  7. 7.Graduate Institute of Humanities in MedicineTaipei Medical UniversityTaipeiTaiwan
  8. 8.Department of Radiation OncologyShuang Ho HospitalTaipeiTaiwan

Personalised recommendations